Posology: Adults and children (above 5 years of age): Menveo should be administered as a single 0.5 ml injection.
Children (2-5 years of age): Menveo should be administered as a single 0.5 ml injection. A second dose may be administered 2 months after the first dose.
Elderly: There are limited data in individuals aged 56-65 and there are no data in individuals aged >65 years.
Booster vaccination: Long-term antibody persistence data following vaccination with Menveo are available up to 5 years after vaccination (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.
Paediatric population (under 2 years of age): The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in Pharmacology: Pharmacodynamics under Actions but no recommendation on a posology can be made.
Method of administration: Menveo is given as an intramuscular injection, preferably into the deltoid muscle. It must not be administered intravascularly, subcutaneously or intradermally.
Separate injection sites must be used if more than one vaccine is being administered at the same time.
For instructions on preparation and reconstitution of the product, see Special precautions for disposal and other handling under Cautions for Usage.